FDA Prescription Drug User Fee Program Will Get OIG Appraisal
This article was originally published in The Pink Sheet Daily
Executive Summary
In addition to user fees, upcoming FDA reviews will also focus on oversight of post-marketing requirements and information exchange in the drug supply chain.
You may also be interested in...
PDUFA VI: Innovative Trial Design Talks Can’t Have Formal Meeting Goals, FDA Says
FDA tells industry that proposal on trials also can’t use SPA-like process.
Medicare Seeks Input On Dispute Resolution, Civil Penalties For Rx Pricing Program
Calculating a ‘fair price’ for new versions of already negotiated moiety is also one of several that CMS is requesting input on in its recently released initial guidance on the negotiation program.
Pink Sheet Podcast: Medicare Inflation Rebates And Negotiation, Leqembi Reimbursement, US FDA Gene Therapy Chief
Pink Sheet reporter and editors discuss the first round of mandated Medicare inflation rebates and new guidance on price negotiations, consider the VA’s decision to cover the Alzheimer’s drug Leqembi, and the US FDA continuing to search for a cell and gene therapy office leader.